F-group (family)
5054.1.1.59 Ion_trans, Ion_trans_2
Ligands and drugs
801
Member domains
340
with ligand contacts (≤ 4 Å)
42.4% of members
216
with DrugDomain annotations
27.0% of members
57
with a DrugBank compound
7.1% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5054.1.1.59 belongs to X-group 5054 Voltage-gated ion channels, which binds 10.4 ligand superclasses per 20 proteins, broader than 97% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04540 | CLR | Cholesterol | 28 |
| DB06637 | — | — | 16 |
| DB04953 | FBX | Ezogabine | 7 |
| DB11403 | 8I2 | Emodepside | 4 |
| DB00321 | — | Amitriptyline | 3 |
| DB00458 | — | Imipramine | 3 |
| DB11633 | — | Isavuconazole | 3 |
| DB00280 | — | — | 2 |
| DB00939 | — | Meclofenamic acid | 2 |
| DB00996 | — | Gabapentin | 2 |
| DB04855 | — | — | 2 |
| DB06217 | — | — | 2 |
| DB00356 | — | Chlorzoxazone | 1 |
| DB00436 | — | — | 1 |
| DB00637 | — | Astemizole | 1 |
| DB00753 | — | Isoflurane | 1 |
| DB00774 | — | Hydroflumethiazide | 1 |
| DB00845 | — | — | 1 |
| DB00999 | — | Hydrochlorothiazide | 1 |
| DB01028 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| Kmetal | POTASSIUM ION | 197 |
| PGW | (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl(9Z)-octadec-9-enoate | 54 |
| POV | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate | 48 |
| CLR | CHOLESTEROL | 32 |
| 6PL | (4S,7R)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSAN-1-AMINIUM 4-OXIDE | 12 |
| 9MF | methyl N-[4-[(4-fluorophenyl)methyl-prop-2-ynyl-amino]-2,6-dimethyl-phenyl]carbamate | 12 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 12 |
| QNJ | (3beta,5beta,14beta,17alpha)-cholestan-3-ol | 12 |
| QNP | (2S)-1-(nonanoyloxy)-3-(phosphonooxy)propan-2-yl tetradecanoate | 12 |
| PIO | [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate | 9 |
| D21 | (2R)-1-(hexadecanoyloxy)-3-(phosphonooxy)propan-2-yl (9Z)-octadec-9-enoate | 8 |
| FBX | ethyl N-[2-azanyl-4-[(4-fluorophenyl)methylamino]phenyl]carbamate | 8 |
| GB9 | N-(6-chloranylpyridin-3-yl)-4-fluoranyl-benzamide | 8 |
| P0T | cannabidiol | 8 |
| PT5 | [(2R)-1-octadecanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propan-2-yl] (8Z)-icosa-5,8,11,14-tetraenoate | 6 |
| 1II | 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1~{H}-benzimidazol-2-one | 4 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 4 |
| 7PN | N-(1,2-dihydroacenaphthylen-5-yl)-4-fluoranyl-benzamide | 4 |
| 7Q0 | N-(4-azanyl-1,2-dihydroacenaphthylen-5-yl)-4-fluoranyl-benzamide | 4 |
| 8H5 | Verruculogen | 4 |